Acredit’s own Yvonne Andersson has co-authored a new paper on the cytoplasmic expression of CD133 in cancer stem cells (CSCs). Cancer stem cells are known for their ability to self-renew and their role in tumorigenicity, but the prognostic significance of CSCs is not well understood. Yvonne, along with researchers from the Iran University of Medical Sciences and the State University of New York at Buffalo, looked into the association between CD133 expression and clinicopathological features of CSCs in renal cell carcinoma and found that CD133 expression appears to be higher in more aggressive cells. This indicates that CD133 could be an important biomarker in the prediction of potential cancer progression. Read more about CD133 here.
- Cure4PMP Meeting – Paris
- Acredit Network Conference at Losby Gods